Morgan Stanley Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)
I'm PortAI, I can summarize articles.
According to TipRanks, Frommer is a 2-star analyst with an average return of 0.5% and a 53.54% success rate. Frommer covers the Healthcare sector, focusing on stocks such as Galapagos, PTC Therapeutics, and Zenas BioPharma, Inc.. Currently, the analyst consensus on Arcutis Biotherapeutics is a Strong Buy with an average price target of $22.79, an 8.99% upside from current levels. In a report released on October 6, Needham also maintained a Buy rating on the stock with a $22.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments